West Highlights Integrated Solutions Offering and Related Technical and Regulatory Expertise at Upcoming Industry Events
EXTON, Pa., Oct. 8, 2018
EXTON, Pa., Oct. 8, 2018 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will introduce a new Integrated Solutions Program to help to reduce risk, mitigate regulatory complexity and simplify the journey from molecule to market for pharmaceutical partners at the PDA Universe of Prefilled Syringes and Injection Devices (PDA) and CPhI Worldwide conferences. In addition, West will highlight its industry expertise through a number of technical- and regulatory-focused PDA presentations.
West's new Integrated Solutions Program will provide customers with a comprehensive approach to drug containment and delivery system development. Available in defined and customized packages, the new offering will combine West's suite of drug packaging and delivery products with West's proven expert testing and support services, to meet the unique needs of the drug product and its delivery system at any stage of development, across all injectable formats.
"Our customers are under increasing pressure to move new therapies to market quickly while maintaining cost efficiencies – all while enduring increased regulatory scrutiny," said Karen Flynn, SVP & Chief Commercial Officer, West. "West's new Integrated Solutions Program will allow our customers to efficiently leverage our extensive knowledge of primary containment and delivery systems and advanced analytical testing capabilities to manage the regulatory landscape while helping to reduce development and supply risk, accelerate path to market, minimize total cost of ownership and improve the patient experience."
While the Integrated Solutions Program is new, West has well-established quality and regulatory expertise, which will be featured in the following poster and panel presentations at PDA:
- October 8—3:45 to 5:15 p.m.—B2: Building Clarity in Addressing Regulatory Challenges for Combination Products, Moderated by Fran DeGrazio, Vice President, Scientific Affairs & Technical Services, West
- October 8—3:15 to 3:45 p.m.—What's New with the Regulations? A Well-Rounded Approach to Regulatory Performance Testing for Combination Products, Daniel L. Bantz, Technology Manager, West
- October 9—7:15 to 7:40 a.m.—Impact of Excipients on Functionality, Liang Fang, Principal Research Scientist, West (co-presented with Galen Shi, PhD, Advisor, Eli Lilly and Company)
- October 8 and October 9—10:00 to 10:45 a.m. and 3:00 to 3:45 p.m.— Gx RTF® syringes and NovaPure™ plunger stoppers, Katie Espenshade, SME Specialist, CZ, PDS, Combination Products, West (co-presented with Maximilian Vogl, Global Head of Product Management Gx® Solutions, Gerresheimer)
At CPhI Worldwide, in recognition of West's enduring commitment to both quality and corporate sustainability, West will be highlighted as a finalist in the CPhI Awards for Excellence in Pharma for the categories of Supply Chain, Logistics and Distribution and Corporate Social Responsibility. The CPhI Awards for Excellence in Pharma celebrate companies that turn inspiration into innovation to drive the pharmaceutical industry forward.
In addition to showcasing its full portfolio of drug containment and delivery technologies, West will also introduce Daikyo's D Sigma® stoppers at CPhI Worldwide. Available in Ready-to-Use-Validated (RUV®) and Ready-to-Sterilize-Validated (RSV®) formats, Daikyo D Sigma high-quality elastomer components combine advanced technology and expertise to provide the tightest particulate specification in the Daikyo portfolio and 100 percent dimensional verification, helping to reduce variability and mitigate potential risks to patient safety.
For more information on West products and services, including Daikyo Crystal Zenith® containment & delivery systems, its Westar® Select quality enhancement offering, NovaPure™ components, SelfDose™ patient-controlled injector and SmartDose™ drug delivery platform, visit Booth #506 at PDA Universe of Prefilled Syringes and Injection Devices, October 8-9, in Orlando, FL; Booth #4C22 at CPhI Worldwide October 9-11, in Madrid, Spain; or West online at www.westpharma.com.
Certain forward-looking statements are included in this press release. They use such words as "will," "new," "proven," "allow," "reduce," "accelerate," "minimize," "improve" and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations or that the services will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customer decisions to move forward with our new service offerings and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause the Company's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2017 net sales of $1.6 billion reflect the daily use of approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
West and the diamond logo, Westar®, NovaPure™ and SelfDose™ are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
SmartDose™ is a trademark of West Pharma. Services IL, Ltd, a subsidiary of West Pharmaceutical Services, Inc.
Daikyo D Sigma®, RUV®, RSV®, and Crystal Zenith® are registered trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith® technology is licensed from Daikyo Seiko, Ltd.
RTF® is a registered trademark of Gerresheimer Bunde GmbH.
Gx® is a registered trademark of Gerresheimer Glas GmbH.
Senior Director, Global Communications
View original content to download multimedia:http://www.prnewswire.com/news-releases/west-highlights-integrated-solutions-offering-and-related-technical-and-regulatory-expertise-at-upcoming-industry-events-300725369.html
SOURCE West Pharmaceutical Services, Inc.